{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036288","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.151851+00:00","generated_at":"2026-05-31T10:49:08.687269+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PDS Biotech to present updated Versamune HPV Phase 2 data at ASTRO 2024","bullets":["Updated IMMUNOCERV Phase 2 data for Versamune® HPV (PDS0101) with chemoradiation in locally advanced cervical cancer accepted for oral presentation at ASTRO 2024.","Presentation scheduled for Oct 1, 2024, 2:50-3:00 p.m. ET; lead author Dr. Adam Grippin from MD Anderson.","No specific efficacy results disclosed in this press release; investors await presentation for updated data."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036288","json":"https://secwatch.observer/filing/0001140361-24-036288.json","markdown":"https://secwatch.observer/filing/0001140361-24-036288.md","text":"https://secwatch.observer/filing/0001140361-24-036288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124036288/0001140361-24-036288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124036288/ef20033761_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:49:08.687269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}